Akums Secures Patent for Innovative Sickle Cell Disease Medication

Akums Drugs and Pharmaceuticals received a patent for their stable oral suspension of Hydroxyurea, tailored for Sickle Cell Disease (SCD). This affordable formulation aims to reduce dependency on imported medicines, offering a cost-effective solution for patients, particularly in India and Africa.

Akums Drugs and Pharmaceuticals announced on Friday that it has successfully been granted a patent for a new formulation designed to treat Sickle Cell Disease (SCD). The India patent office issued the patent for the room temperature stable oral suspension of Hydroxyurea.

According to Akums Managing Director Sanjeev Jain, the company's ongoing mission is to develop affordable medicines for Orphan Drugs. Jain emphasized the goal of reducing reliance on imported medicines and ensuring patient safety with timely and essential treatments.

Sickle Cell Disease is a genetic blood disorder causing severe health issues, including anemia and frequent pain episodes, impacting millions globally, especially in India and Africa. Akums highlights that their new formulation will be significantly more economical than existing imported Hydroxyurea solutions.

(With inputs from agencies.)